Substance Abuse and Mental Health Services Administration (SAMHSA)
Resources and Tools
Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
This month, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), announced three funding opportunities to strengthen mental health and substance use systems and services for people with or affected by HIV:
In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
This policy brief identified states potentially at risk for an HIV or HCV outbreak and used data from multiple sources to examine rural-urban differences in 1) state-level infectious disease surveillance, prevention activities, and collaboration with stakeholders; 2) local health department-level
Because of naloxone’s ability to reverse opioid overdose and its ease of use, by July 15, 2017, all 50 states and the District of Columbia had passed legislation to improve naloxone access, as one strategy to reduce opioid overdose morbidity and mortality.
This Advisory offers guidance to providers and administrators in SUD treatment programs on screening clients for hepatitis A, hepatitis B, and hepatitis C infections, as well as action steps for the treatment and support of clients with a viral hepatitis infection and a SUD.
This Advisory highlights strategies and considerations for substance use disorder (SUD) treatment providers to integrate HIV services into their practice and effectively engage people with HIV in SUD treatment.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.